14 chemin des Aulx
1228 Plan les Ouates
6 articles with Prexton Therapeutics
It’s been a big year so far for activity in the U.S. biopharma market—record IPOs and plenty of big acquisitions. But things may be heating up in Europe as well.
3/16/2018Lunbeck is acquiring Prexton Therapeutics BV, a 2012 spinout from Merck KgaA, and its Phase II treatment for Parkinson’s disease.
Forbion’s Portfolio Company, Prexton Therapeutics Acquired by Lundbeck for up to EUR 905 million (USD 1.1 billion)
Upfront payment of EUR 100 million plus up to EUR 805 million in development, regulatory and sales milestones; Foliglurax – a first-in-class development candidate for Parkinson’s disease in Phase II clinical development; Prexton sale marks third successful exit from Forbion’s most recent fund, Forbion III